AbbVie has built a recession-resistant portfolio by focusing on life-saving and chronic therapies across immunology, oncology and neuroscience. Even after the loss of Humira exclusivity, the company demonstrated its R&D strength by bringing newer assets to market, mitigating the patent cliff. Its noncyclical product mix supports stable demand profiles, which has historically allowed AbbVie to outperform broader market downturns.

With a market capitalization of approximately $396 billion, AbbVie maintains a gross margin near 69.7% and averages 5.7 million shares traded daily. The company has increased its dividend for 54 consecutive years, marking it as a Dividend King, and currently yields around 2.93%. This track record underscores its ability to generate cash flow and return capital to shareholders even during challenging market conditions.

Investors are closely watching AbbVie's immunology franchise to offset Humira’s post-exclusivity decline. Management expects fourth-quarter immunology revenues to grow in the mid-teens percentage range, led by Skyrizi, which is projected to record year-over-year growth above 25%, and Rinvoq, anticipated to expand near 30%. These two brands are poised to contribute more than $6 billion in combined quarterly sales, underscoring their critical role in AbbVie's near-term growth strategy.